I have a feeling that patient has ovarian cancer, since the whole PR is about the Phase 2 trial. The bar isn't set very high for approval. The medium overall survival of Roche's Avastin + chemotherapy is 16.6 months in Phase 3, whereas the OS of chemotherapy alone is 13.3 months. That particular patient, if it's ovarian cancer, has surpassed 13 months and is approaching 16 months.

Quote:

---

sox0407 you don't believe that patient who has been in the trial 15 months is a ovarian cancer patient do you?

---